title: Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole.
abstract: Treatment of Scedosporium apiospermum mycetoma usually requires limb amputation. A 49-year-old woman, from Ivory Coast, was diagnosed with Madura foot in 1995. She failed to respond to several treatments including itraconazole, fluconazole and co-trimoxazole, and refused limb amputation. In December 2002 she was admitted to hospital in France with a painful, swollen right leg and foot. She had no fever and C-reactive protein was 120 mg/l. Magnetic resonance imaging (MRI) confirmed the destruction of tarsus bones with a tibia extension. Voriconazole (400 mg/day) treatment was initiated in March 2003; a significant clinical improvement was observed within 4 months as confirmed by C-reactive protein (16 mg/l) and MRI. Voriconazole was maintained for 18 months with good tolerance. Cholestasis appeared after the first month and remained stable. In October 2004 voriconazole was discontinued due to side effects on the liver (alanine aminotransferase 17 times the normal level); MRI showed impressive regression of bone lesions. As of July 2005, the patient remains clinically well. Voriconazole appears to be a promising drug for the treatment of S. apiospermum mycetomas.
authors.affiliation: Department of Infectious and Tropical Diseases, Purpan University Hospital, 31059 Toulouse Cedex, France. porte.l@chu-toulouse.fr
authors.forename: L
authors.initials: L
authors.lastname: Porte
authors.forename: S
authors.initials: S
authors.lastname: Khatibi
authors.forename: L El
authors.initials: LE
authors.lastname: Hajj
authors.forename: S
authors.initials: S
authors.lastname: Cassaing
authors.forename: A
authors.initials: A
authors.lastname: Berry
authors.forename: P
authors.initials: P
authors.lastname: Massip
authors.forename: M D
authors.initials: MD
authors.lastname: Linas
authors.forename: J F
authors.initials: JF
authors.lastname: Magnaval
authors.forename: N
authors.initials: N
authors.lastname: Sans
authors.forename: B
authors.initials: B
authors.lastname: Marchou
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001850:Bone Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D008271:Mycetoma / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000627:therapeutic use*; D021681:Scedosporium; D013639:Tarsal Bones / Q000382:microbiology / Q000473:pathology; D013977:Tibia / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole